Chronic Kidney Disease-Mineral Bone Disorder

CKD-Mineral and Bone Disorder (CKD-MBD) refers to a systemic disorder of mineral and bone metabolism due to chronic kidney disease (usually stage G3b–G5), characterized by:

• Abnormalities in calcium, phosphate, PTH, or vitamin D metabolism
• Bone pathology (renal osteodystrophy)
• Vascular or soft tissue calcification

It is strongly associated with increased cardiovascular morbidity and mortality in CKD patients.

Pathophysiology

 Key Drivers:

1. Phosphate Retention
   ↓ GFR → ↓ phosphate excretion → hyperphosphatemia
2. Hypocalcemia
   • Phosphate binds calcium in blood → ↓ free serum calcium
   • ↓ 1α-hydroxylase activity → ↓ conversion of 25(OH)D to 1,25(OH)₂D (calcitriol) → ↓ intestinal calcium absorption
3. Secondary Hyperparathyroidism
   • Hypocalcemia + hyperphosphatemia + low calcitriol → ↑ PTH secretion
   • Chronic elevation → parathyroid hyperplasia → bone resorption and eventually tertiary hyperparathyroidism

Typical Laboratory Findings

Marker	Finding in CKD-MBD
Serum Phosphate	↑ (Hyperphosphatemia)
Serum Calcium	↓ or low-normal
Parathyroid Hormone (PTH)	↑
1,25(OH)₂ Vitamin D	↓
Alkaline Phosphatase (ALP)	↑ in high bone turnover

 

Clinical Features

• Skeletal : Bone pain, fractures, skeletal deformities (renal osteodystrophy)
• Extraskeletal : Vascular calcification, soft tissue calcification, pruritus
• Cardiovascular : Arterial stiffness, valvular calcification → ↑ cardiovascular mortality

Diagnostic Criteria (KDIGO)

CKD-MBD includes:

• Biochemical abnormalities
• Bone abnormalities (renal osteodystrophy)
• Vascular/soft tissue calcification

Management Principles

Therapeutic Goals

• Normalize serum calcium
• Maintain serum phosphate < 1.8 mmol/L (~5.5 mg/dL)
• Maintain PTH within 2–3× upper limit of normal (ULN)
• Prevent vascular/soft tissue calcification

1. Phosphate Management

• Dietary phosphate restriction
• Phosphate binders :
  • Calcium-based : calcium acetate, calcium carbonate
  • Non-calcium (used if hypercalcemia is present):
    • Sevelamer (non-absorbable polymer)
    • Lanthanum carbonate
    • Iron-based binders (e.g., ferric citrate)

2. Vitamin D Supplementation

• Used to suppress PTH and correct hypocalcemia
• Forms:
  • Calcitriol (1,25(OH)₂D)
  • Alfacalcidol (1α-hydroxyvitamin D)
• Use cautiously in patients at risk of hypercalcemia or hyperphosphatemia

3. Calcimimetics

• Cinacalcet : Increases calcium sensitivity of the parathyroid gland → ↓ PTH secretion
• Used in:
  • Secondary hyperparathyroidism unresponsive to vitamin D
  • High calcium/phosphate levels
  • Dialysis patients

4. Parathyroidectomy

• Consider in severe, refractory secondary or tertiary hyperparathyroidism not responding to medical therapy

Important Notes

• Hypercalcemia in CKD is concerning and may:
  • Worsen renal function
  • Suggest tertiary hyperparathyroidism or vitamin D/calcium overtreatment
• Avoid aluminum-containing binders due to risk of aluminum toxicity (encephalopathy, osteomalacia)

 High-Yield Pearls

• CKD-MBD is a systemic disorder , not just a bone problem.
• Vascular calcification , especially coronary artery and aortic valve calcification, is a key contributor to mortality in CKD.
• Monitor calcium, phosphate, ALP, and PTH regularly in CKD stage 3 and beyond.
• Calcium and phosphate should not both be elevated —risk of calciphylaxis.

 Target Lab Ranges 

Marker	Target in CKD G3b–G5
Phosphate	< 1.8 mmol/L (< 5.5 mg/dL)
Calcium	Normal range (8.5–10.2 mg/dL)
PTH	2–9 × ULN (depending on CKD stage)
Ca × P product	< 55 mg²/dL²

---